Generally speaking, mild gastritis, i.e. superficial gastritis, does not increase the risk of gastric cancer, but if not adjusted in time, it may further develop into atrophic gastritis, which is a state of "precancerous lesion".
On April 4, 2015, the 100-year-old active swimmer Mieko Nagaoka (living in Tabushi Town, Yamaguchi Prefecture, Japan) successfully completed the women's 1500-meter freestyle competition and became the world's first swimmer in the age group of 100-104.
Fujifilm Corporation and the National Center for Psychiatric and Neurological Research have announced positive research results using Fujifilm's new AI technology to predict whether a patient with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) within two years.
Eye cancer is a very dangerous disease, and as the disease develops, it will affect the patient's body more and more, so it is important for eye cancer patients to receive timely treatment.
In today's rapidly changing world of science and technology, a research result that sounds very sci-fi will appear from time to time. No, a paper published in the journal Science Robotics belongs to this scope: a cell regeneration robot that successfully works in vivo.
Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.
The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
Data from a study presented at the annual meeting of the European Society of Medical Oncology in 2022 showed that lenvatinib in combination with Pembrolizumab could give 100% efficacy in this group of patients.
A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.
